Chemical-pharmaceutical intermediates are fine chemicals in the production process from chemical-pharmaceutical raw materials to raw materials or drugs. The synthesis of chemical drugs depends on high quality pharmaceutical intermediates. This type of chemical does not require a pharmaceutical production license and can be produced in an ordinary chemical industry.

As long as it reaches a certain level, it can be used for the synthesis of pharmaceutical products. Our country needs more than 2,000 kinds of raw materials and intermediates for the chemical industry every year, and the demand is over 2.5 million tons. After years of development, the chemical raw materials and intermediates needed for the pharmaceutical’s production in my country can basically be combined.

There are many types of pharmaceutical intermediates, which can be divided into antibiotic intermediates, antipyretic and analgesic intermediates, cardiovascular system pharmaceutical intermediates and anticancer pharmaceutical intermediates, according to the application fields.

There are many types of specific pharmaceutical intermediates, such as imidazole, furan, phenol intermediates, aromatic intermediates, pyrrole, pyridine, biochemical reagents, sulfur-containing, nitrogen-containing, halogen compounds, heterocyclic compounds, starch, mannitol, microcrystalline cellulose, lactose, dextrin, glycols, powdered sugar, inorganic salts, ethanol intermediates, stearates, amino acids, ethanolamines, potassium salts, sodium salts and other intermediates, etc. Wait.

In addition, in recent years, due to increasingly stringent regulatory requirements for medicines, the growing difficulty in drug research and development, and rising prices, multinational pharmaceutical companies have had to shorten the time to market for patented drugs, reduce R& D and production costs, and maintain good performance throughout the drug’s life cycle.

Profit space, improve your own operational efficiency and gradually transform from a “vertical integration” business model to a “development cooperation” business model. The commercial ties of research, development and production of patented drugs are professionally broken down and outsourced to contracted pharmaceutical research companies, professional institutions,